Evidence map›Paper›PMID 22492561›Full record

ArticleBrain : a journal of neurology2012

Essential role of interleukin-6 in post-stroke angiogenesis.

Karen Gertz, Golo Kronenberg, Roland E Kälin, Tina Baldinger, Christian Werner, Mustafa Balkaya, Gina D Eom, Julian Hellmann-Regen, Jan Kröber, Kelly R Miller and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 1 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 1 synthesis or guideline pooled it, 200 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Karen GertzDepartment of Neurology, Charité– Universitätsmedizin Berlin, 10117 Berlin, Germany.
Golo Kronenberg
Roland E Kälin
Tina Baldinger
Christian Werner
Mustafa Balkaya
Gina D Eom
Julian Hellmann-Regen
Jan Kröber
Kelly R Miller
Ute Lindauer
Ulrich Laufs
Ulrich Dirnagl
Frank L Heppner
Matthias Endres
Charité - Universitätsmedizin Berlin · DESaarland University · DEMax Delbrück Center · DE

Funding

Vaccination and microglia in Alzheimer's mouse modelsR01NS046006 · NINDS · UNIVERSITY OF ZURICH · PI HEPPNER, FRANK L · 2005 to 2009
$843k
NINDS NIH HHS R01 NS046006
6 · The paper itself

Abstract

Ambivalent effects of interleukin-6 on the pathogenesis of ischaemic stroke have been reported. However, to date, the long-term actions of interleukin-6 after stroke have not been investigated. Here, we subjected interleukin-6 knockout (IL-6(-/-)) and wild-type control mice to mild brain ischaemia by 30-min filamentous middle cerebral artery occlusion/reperfusion. While ischaemic tissue damage was comparable at early time points, IL-6(-/-) mice showed significantly increased chronic lesion volumes as well as worse long-term functional outcome. In particular, IL-6(-/-) mice displayed an impaired angiogenic response to brain ischaemia with reduced numbers of newly generated endothelial cells and decreased density of perfused microvessels along with lower absolute regional cerebral blood flow and reduced vessel responsivity in ischaemic striatum at 4 weeks. Similarly, the early genomic activation of angiogenesis-related gene networks was strongly reduced and the ischaemia-induced signal transducer and activator of transcription 3 activation observed in wild-type mice was almost absent in IL-6(-/-) mice. In addition, systemic neoangiogenesis was impaired in IL-6(-/-) mice. Transplantation of interleukin-6 competent bone marrow into IL-6(-/-) mice (IL-6(chi)) did not rescue interleukin-6 messenger RNA expression or the early transcriptional activation of angiogenesis after stroke. Accordingly, chronic stroke outcome in IL-6(chi) mice recapitulated the major effects of interleukin-6 deficiency on post-stroke regeneration with significantly enhanced lesion volumes and reduced vessel densities. Additional in vitro experiments yielded complementary evidence, which showed that after stroke resident brain cells serve as the major source of interleukin-6 in a self-amplifying network. Treatment of primary cortical neurons, mixed glial cultures or immortalized brain endothelia with interleukin 6-induced robust interleukin-6 messenger RNA transcription in each case, whereas oxygen-glucose deprivation did not. However, oxygen-glucose deprivation of organotypic brain slices resulted in strong upregulation of interleukin-6 messenger RNA along with increased transcription of key angiogenesis-associated genes. In conclusion, interleukin-6 produced locally by resident brain cells promotes post-stroke angiogenesis and thereby affords long-term histological and functional protection.

Indexed as

Analysis of VarianceAngiogenic ProteinsAnimalsBone Marrow TransplantationBrainCalcium-Binding ProteinsCells, CulturedCerebral CortexCytokine Receptor gp130CytokinesDisease Models, AnimalEmbryo, MammalianEndothelial CellsEndothelin-1Enzyme-Linked Immunosorbent AssayGait Disorders, NeurologicAif1 protein, mouseAngiogenic ProteinsCalcium-Binding ProteinsCytokine Receptor gp130CytokinesEndothelin-1GlucoseGreen Fluorescent ProteinsIl6st protein, mouseInterleukin-6Microfilament ProteinsReceptor, trkBSTAT3 Transcription FactorTetrazolium SaltsThiazolesthiazolyl blue

Identifiers

PMID22492561
PMCPMC3359750
OpenAlexW2084977288

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.